Back to Search
Start Over
Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects
- Source :
- Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
- Publication Year :
- 2020
- Publisher :
- Nature Publishing Group, 2020.
-
Abstract
- Destruction of the alveolar bone in the jaws can occur due to periodontitis, trauma or following tumor resection. Common reconstructive therapy can include the use of bone grafts with limited predictability and efficacy. Romosozumab, approved by the FDA in 2019, is a humanized sclerostin-neutralizing antibody (Scl-Ab) indicated in postmenopausal women with osteoporosis at high risk for fracture. Preclinical models show that Scl-Ab administration preserves bone volume during periodontal disease, repairs bone defects surrounding dental implants, and reverses alveolar bone loss following extraction socket remodeling. To date, there are no studies evaluating Scl-Ab to repair osseous defects around teeth or to identify the efficacy of locally-delivered Scl-Ab for targeted drug delivery. In this investigation, the use of systemically-delivered versus low dose locally-delivered Scl-Ab via poly(lactic-co-glycolic) acid (PLGA) microspheres (MSs) was compared at experimentally-created alveolar bone defects in rats. Systemic Scl-Ab administration improved bone regeneration and tended to increase cementogenesis measured by histology and microcomputed tomography, while Scl-Ab delivered by MSs did not result in enhancements in bone or cemental repair compared to MSs alone or control. In conclusion, systemic administration of Scl-Ab promotes bone and cemental regeneration while local, low dose delivery did not heal periodontal osseous defects in this study.
- Subjects :
- 0301 basic medicine
Osteoporosis
Romosozumab
Dentistry
lcsh:Medicine
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Medicine
Bone regeneration
lcsh:Science
Dental alveolus
Periodontitis
Multidisciplinary
business.industry
fungi
lcsh:R
medicine.disease
Cementogenesis
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
Systemic administration
Sclerostin
lcsh:Q
business
Subjects
Details
- Language :
- English
- ISSN :
- 20452322
- Volume :
- 10
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Scientific Reports
- Accession number :
- edsair.doi.dedup.....492628d4250c8e0754a39d1cc47a6b4d